Compared with just 5 years ago, adjuvant therapy for stage III melanoma has undergone a major transformation. Immune checkpoint blockade and targeted therapies already approved in the metastatic stage IV melanoma setting have now been approved in the earlier adjuvant setting, providing long-awaited effective treatment options for patients for whom interferon-alfa 2b was the mainstay of approved therapy since its approval in 1995. The decision about whether to prescribe a specific adjuvant therapy entails careful selection of patients on the basis of risk of disease relapse and likelihood of therapeutic efficacy, because, unlike in the metastatic setting, clinical response cannot be readily assessed, owing to the absence of measurable disease.

中文翻译：

---

黑色素瘤的辅助治疗：如何选择？

与仅仅5年前相比，III期黑色素瘤的辅助治疗已经发生了重大变化。现已在较早的辅助治疗中批准了在转移性IV期黑色素瘤治疗中已经批准的免疫检查点阻滞和靶向治疗，为自2006年获得批准以来干扰素-α2b成为主要治疗手段的患者提供了期待已久的有效治疗选择1995年。是否开具特定辅助治疗的决定需要根据疾病复发的风险和治疗效果的可能性来仔细选择患者，因为与转移性疾病不同，由于缺乏转移性疾病，临床反应不易评估可衡量的疾病。